Welcome

Investor Contact

Media & Investor Relations:
Troy Wichterman
Chief Financial Officer
(425) 402 - 1400
twichterman@biolifesolutions.com

Transfer Agent

Broadridge Corporate Issuer Solutions, Inc.
P.O. Box 1342
Brentwood, New York 11717
USA
(877) 830 - 4936
shareholder@broadridge.com

Investor Alerts

Investor Home

Investor Presentation

BioLife Solutions Investor Presentation January 2024

Recent Events

BioLife Solutions, Inc. Q2 2024 Earnings Conference Call and Business Update

Thursday, August 8, 2024

1:30pm - 2:30pm PDT

Latest News

Get News Alerts by Email

Aug 08, 2024

BioLife Solutions Reports Second Quarter 2024 Financial Results

Cell Processing revenue increased 11% sequentially to $18.0 million GAAP gross margin of 51% and non-GAAP adjusted gross margin of 52% GAAP net loss from continuing operations of $7.1 million and...

Jul 25, 2024

BioLife Solutions to Report Second Quarter 2024 Financial Results and Business Update on August 8, 2024

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced...

View All News and Press Releases